1995
 
 -Smruthi Organics  a bulk drug manufacturing company has decided to
 expand its product range by the introduction of Ciprofloxacin
 (antibiotic) and Ranitidine HCl. To part finance this project  the
 company is entering the capital market on December 4th  with a public
 issue of 18 88 550 lakh equity shares of Rs. 10 each at a premium of
 Rs. 5 per share.
 
 
 2005
 
 - The Company's Block No C and D being dedicated for exports and
 received 100% EOU status permission from the Development
 Commissioner, Seepz, Mumbai and started the activities.
 
 
 2006
 
 - The Company has created new facility i.e.; additional production
 plant viz. 'E' Block' at the Company's Factory No. Unit II Plot No
 A-27, MIDC, Chincholi, Solapur has commenced the commercial operation
 as an Export Oriented Unit.
 
 - The Board of Directors have recommended a dividend of 25% for the
 financial year.
 
 
 2007
 
 - The Company has been accredited the Current Good Manufacturing
 Practices - World Health Organization (cGMP - WHO) certificate from
 German Health Authorities (Landesamt fur Gesundheist and Soziales
 Berlin, Germany) for Active Pharmaceutical Ingredients (API) viz.
 Norfloxacin, Carbidopa and Metformin Hydrochloride for the European
 Union.
 
 
 2009
 
 - Amlodipine Besilate (API) has been granted Certificate of
 Suitability (COS) by European Directorate from the Quality of
 Medicines and Healthcare (EDQM). This recognition shall immensely
 help the Company to Enter EU Regulatory business in EU Countries.
 
 
 2011
 
 - Smruthi Orga - Manufacturing site U-II received USFDA approvals.
 
 - Recommendation of Dividend @ 25% on Equity Shares i.e. Rs. 2.50 per
 share.
 
 
 2012
 
 - The Board of Directors has recommended a dividend of 30% on Equity
 Shares of Rs. 10/- each for the year.